12/7 COPD - Hussain Flashcards

1
Q

COPD

A

chronic obstructive pulmonary disease

irreversible airflow obstruction and persistent inflammation

  • bronchiectasis
  • asthma (reversible)
  • emphysema
  • chronic bronchitis
  • cystic fibrosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

chronic bronchitis

A

basics

  • chronic cough and sputum production for at least 3 months per year for 2 conseutive years
  • men more commonly affected
  • primary risk factor: smoking

pathophysiology

  • mucous metaplasia
  • difficulty clearing secretions due to
    • poor ciliary fx
    • distal airway occlusion
    • ineffective cough secondary to resp muscle weakness, reduced peak exp flow
  • airflow obstruction
    • mucus hypersecretion → luminal occlusion
    • epithelial layer thickens → luminal narrowing
    • incr mucus alters airway surface tension → lumen predisposed to collapse

***diffuse disease : need to remember when trying to effect V/Q mismatch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what causes inflammation?

A
  • inhaled noxious stimuli (cig smoke, etc)
  • incr neutrophils in airway lumen
  • macrophages in airway lumen, wall, parenchyma
  • CD8 lymphocytes in airway wall and parenchyma
    • contrast: asthmatics have more CD4 lymphocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

causes of COPD

A

smoking

  • nicotine stimulates SNS →
    • incr HR
    • peripheral vasoconstriction
    • incr bp and cardiac work

infection

  • major contributing factor to aggravation and progression of COPD

heredity

  • alpha-antitrypsin deficiency
    • accounts for < 1% of COPD cases
    • AAT produced by liver, found in lungs
    • deficiency → lysis of lung tissue by proteolytic enzymes from neutrophils and macrophages → emphysema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

alpha1AT deficiency

two types/causes

result?

A
  • alpha-antitrypsin deficiency accounts for < 1% of COPD cases
  • AAT produced by liver, found in lungs
    • deficiency → lysis of lung tissue by proteolytic enzymes from neutrophils and macrophages → emphysema
  1. functional AAT deficiency: smoking → ROS production → inactivation of antiproteases → incr neutrophil elastase
  2. congenital AAT deficiency: incr neutrophil elastase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

emphysema

basics

pathophys: structural changes, later manifestations

A
  • abnormal permanent enlargement of airspace distal to terminal bronchioles
  • accompanied by destruction of bronchioles

pathophysiology

  1. structural changes
  • hyperinflation of alveoli
    • ​as more alveoli coalesce, blebs and bullae can develop
  • destruction of alveolar cap walls
    • reduced SA for oxygen diffusion
    • compensation via incr RR to incr alveolar ventilation
  • narrowed, tortuous small airways
    • air that is trapped causes bronchioles to collapse
  • loss of lung elasticity
    • elastin and collagen destroyed

overall: air trapping (hyperinflation and overdistension)

  1. consequences of emphysema disease process
  • hypoxemia develops late in disease
  • small bronchioles become obstructed due to
    • mucus
    • sm muscle spasm
    • infl process
    • collapse of bronchiolar walls
  • recurrent infection
    • production/stimulation of neutrophils and macrophages
    • release of proteolytic enzymes
    • alveolar destruction
    • infl, exudate, edema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

two types of emphysema

A
  1. centrilobular: central part of lobule destroyed
    * most common
  2. panlobular: whole lobule destroyed
    * usually assoc with AAT deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

emphysema

clinical manifestations

A
  1. dyspnea
    * progresses in severity: fine for a long time → dyspnea on exertion → dyspnea interfering with ADLs and during rest
  2. minimal cough, no to small sputum production
  3. overdistention of alveoli leading to flattening of diaphragm → incr AP diameter
  4. hypoxemia and hypercapnea
    * results from hypoventilation and incr airway resistance, issues with gas exchange
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

complications of COPD

A
  • pulmonary HTN (pulmo vessel constriction due to alveolar hypoxia and acidosis)
  • cor pulmonale (R heart hypertrophy +/- RV failure)
  • pneumonia
  • acute resp failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hypoxemia in COPD

V/Q mismatch in emphysema vs chronic bronchitis

A

emphysema:

  • incr ventilation of poorly perfused lung units → high V/Q ratio
  • incr physiological dead space
  • body compensates by shunting blood to better ventilated areas until it can no longer do so → late hypoxemia

chronic bronchitis:

  • perfusion of underventilated areas → low V/Q ratio
  • ​subsequent physiological shunt
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

shunt

vs

dead space

how do you know if shunt-like hypoxia exists?

A

dead space is caused by ventilated alveoli NOT BEING PERFUSED

  • nonuniform blood flow
  • uniform ventilation
  • (either bc there’s no means for perfusion as in conduction zone or bc there’s an obstruction to perfusion, ex. PE)

shunt is caused by failure of venous blood to reach ventilated alveoli

  • nonuniform ventilation
  • uniform blood flow
  • shunt-like hypoxia test*
  • if you put someone on FiO2 and still cant improve their PaO2, you’ve got a shunt
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

COPD diagnostic studies

CXR, PFTs, arterial blood gas

diff between chronic bronchitis and emphysema PFTs?

A

CXR:

  • early in disease? may not show abnormalities

pulmo fx studies:

  • reduced FEV1/FVC (has to be less than .7)
  • incr residual volume
  • incr total lung capacity

arterial blood gas

  • decr PaO2
    • emphysema late, chronic bronchitis early
  • incr PaCO2 (esp CB)
  • decr pH (esp CB)
  • later stages of COPD, incr HCO3

diff between emphysema and chronic bronchitis PFTs:

  • emphysema involves destruction of parenchyma → affects gas exchange and diffusion capacity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

flow volume loops

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

COPD drug tx

A
  • bronchodilators (maintenance tx)
  • beta-adrenergic agonists (ex. ventolin)
    • MDI or nebulizer preferred
  • anticholinergics (ex. atrovent)

oxygen therapy

  • raises PO2 in inspired air

respiratory therapy

  • pursed lip breating: prolong exhalation, prevent bronchiolar collapse and air trapping
  • diaphragmatic breathing: focuses on using diaphragm instead of accessory muscles → max inhalation, slow RR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

chronic bronchitis vs emphysema

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

bronchiectasis

A

permanent, abnormal widening of bronchi caused by destruction of muscle and elastic tissue

  • results from/assoc with chronic necrotizing infections

occurs in context of chronic airway infection and inflammation

  • causes include postinfectious conditions like bacterial/viral/fungal necrotizing pneumonias,
  • mild to moderate airflow obstruction
  • in bronchiectasis, small airways become obstructed due to inflammatory infiltrate from wall
    • airway dilates → cilia rendered ineffective → mucus can’t be cleared → organisms breed in it!
    • inflammation/infectious process takes hold
17
Q

bronchiectasis etiology

A
  1. postinfectious conditions (ex. necrotizing pneumonias)
  2. congenital/heritary conditions (CF, immunodeficiency, primary ciliary dyskinesia, Kartagener Syndrome)
  3. bronchial obstruction by tumor, foreing bodies, mucus impaction
  4. other conds (rheumatoid arthritis, systemic lupus erythematosus, IBD, post-transplant)
18
Q

primary ciliary dyskinesia

A

autosomal recessive syndrome

variable penetrance

poorly functioning cilia due to absence/shortening of dynein arms

associated syndrome: Kartagener Syndrome:

  • bronchiectasis
  • sinusitus
  • situs inversus
19
Q

cystic fibrosis

A

autosomal recessive genetic disorder

abnormal transport of Cl and Na across epithelium due to mutation of CFTR (cystic fibrosis transmembrane conductance regulator)

  • Delta508 Ch 7
20
Q

bronchiectasis tx

A

***airway clearance***

antibiotics

antiinflammatory tx

prevention of exacerbation

21
Q
A